Hepatoblastoma
Symptoms, Doctors, Treatments, Advances & More

Hepatoblastoma Overview

Save information for later
Sign Up

Learn About Hepatoblastoma

What is the definition of Hepatoblastoma?
Hepatoblastoma is a rare malignant (cancerous) tumor of the live, usually affecting young children. In early stages of the condition, there may be no concerning signs or symptoms. As the tumor gets larger, affected children may experience a painful, abdominal lump; swelling of the abdomen; unexplained weight loss; loss of appetite; and/or nausea and vomiting. The exact underlying cause of Hepatoblastoma is poorly understood. Risk factors for the tumor include prematurity with a very low birth weight, early exposure to hepatitis B infection, biliary atresia, and several different genetic conditions (i.e. Beckwith-Wiedemann syndrome, familial adenomatous polyposis, Aicardi syndrome, Glycogen storage disease, and Simpson-Golabi-Behmel syndrome).
What are the alternative names for Hepatoblastoma?
  • Hepatoblastoma
Who are the top Hepatoblastoma Local Doctors?
Elite in Hepatoblastoma
Dr. John A. Goss
General Surgery
Elite in Hepatoblastoma
Dr. John A. Goss
General Surgery
Referral may be required

Chi St Luke's Health-Baylor St Luke's Medical Center

6720 Bertner Ave, 
Houston, TX 
832-355-1000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

John Goss is a General Surgeon practicing medicine in Houston, Texas. Dr. Goss is rated as an Elite provider by MediFind in the treatment of Hepatoblastoma. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Hepatoblastoma, Liver Failure, Biliary Atresia, Liver Transplant, and Hepatectomy. Dr. Goss is currently accepting new patients.

Elite in Hepatoblastoma
Dr. Rakesh K. Sindhi
General Surgery
Elite in Hepatoblastoma
Dr. Rakesh K. Sindhi
General Surgery
Referral may be required

Atrium Health Transplant Center, A Facility Of Carolinas Medical Center

1025 Morehead Medical Drive, Suite 600, 
Charlotte, NC 
704-355-6649
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Rakesh Sindhi is a General Surgeon practicing medicine in Charlotte, North Carolina. Dr. Sindhi is rated as an Elite provider by MediFind in the treatment of Hepatoblastoma. He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses Hepatoblastoma, Biliary Atresia, Liver Failure, Liver Transplant, and Small Bowel Resection. Dr. Sindhi is board certified in American Board Of Surgery and American Board Of Surgery, Surgery (General Surgery). Dr. Sindhi is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Hepatoblastoma
Elite in Hepatoblastoma
Referral may be required
Hiroshima, JP 

Eiso Hiyama practices practicing medicine in Hiroshima, Japan. Hiyama is rated as an Elite expert by MediFind in the treatment of Hepatoblastoma. They are also highly rated in 5 other conditions, according to our data. Their clinical expertise encompasses Hepatoblastoma, Neuroblastoma, Liver Cancer, Pancreaticoduodenectomy, and Hepato-Pancreato-Biliary Surgery.

View All Doctors
What are the latest Hepatoblastoma Clinical Trials?
A Multi-Center Phase I Study of Codrituzumab in Pediatric Patients With Relapsed or Refractory Glypican 3 (GPC3) Expressing Extra-cranial Solid Tumors
A Multi-Center Phase I Study of Codrituzumab in Pediatric Patients With Relapsed or Refractory Glypican 3 (GPC3) Expressing Extra-cranial Solid Tumors
Enrollment Status: Recruiting
Publish Date: September 01, 2026
Intervention Type: Drug
Study Phase: Phase 1

Summary: The purpose of this study to find out whether codrituzumab is a safe treatment that causes few or mild side effects in children and young adults who have solid tumors that express the protein GPC3. The researchers also want to study the way codrituzumab is absorbed, distributed, and cleared from the body.

Match to trials
Find the right clinical trials for you in under a minute
Get started
LIGHTBEAM-U01 Substudy 01C: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors
LIGHTBEAM-U01 Substudy 01C: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors
Enrollment Status: Recruiting
Publish Date: August 28, 2026
Intervention Type: Biological
Study Phase: Phase 1/Phase 2

Summary: Researchers are looking for new ways to treat children with hepatoblastoma or rhabdomyosarcoma (RMS) that has relapsed or is refractory: * Hepatoblastoma is a common liver cancer in babies and very young children * RMS is a cancer that starts in muscle cells, often in a child's head and neck, bladder, arms, or legs * Relapsed means the cancer came back after treatment * Refractory means the cancer...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center